金陵药业(000919) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥708,534,720.18, representing a 2.24% increase compared to ¥693,016,544.54 in the same period last year[5] - Net profit attributable to shareholders was ¥43,585,110.26, reflecting an 11.07% increase from ¥39,240,141.55 year-on-year[5] - Basic and diluted earnings per share increased by 12.48% to ¥0.0865 from ¥0.0769 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 708,534,720.18, an increase of 2.2% compared to CNY 693,016,544.54 in the same period last year[18] - Net profit for Q1 2023 reached CNY 49,325,374.22, representing a 10.5% increase from CNY 44,443,693.56 in Q1 2022[20] - The total comprehensive income attributable to minority shareholders for Q1 2023 was CNY 5,740,263.96, compared to CNY 5,203,552.01 in Q1 2022, representing an increase of approximately 10.3%[21] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.0865, up from CNY 0.0769 in Q1 2022, reflecting a growth of about 7.4%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching -¥25,354,145.88, a 65.01% increase compared to -¥72,458,661.05 in the previous year[5] - Cash inflow from operating activities totaled CNY 675,761,687.56 in Q1 2023, compared to CNY 626,808,280.41 in Q1 2022, indicating an increase of approximately 7.8%[21] - Cash outflow from operating activities was CNY 701,115,833.44 in Q1 2023, slightly up from CNY 699,266,941.46 in Q1 2022, resulting in a net cash flow from operating activities of -CNY 25,354,145.88, an improvement from -CNY 72,458,661.05 in Q1 2022[21] - Investment activities generated a net cash flow of -CNY 209,375,029.15 in Q1 2023, compared to -CNY 460,424,469.27 in Q1 2022, showing a significant reduction in cash outflow[22] - Cash inflow from financing activities was CNY 3,681,573.36 in Q1 2023, down from CNY 23,616,000.00 in Q1 2022, indicating a decrease of approximately 84.4%[22] - The net increase in cash and cash equivalents for Q1 2023 was -CNY 231,087,932.62, compared to -CNY 524,349,156.37 in Q1 2022, reflecting an improvement in cash management[22] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was CNY 1,243,795,533.31, compared to CNY 957,243,394.73 at the end of Q1 2022, representing an increase of approximately 30%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,521,604,404.57, a slight decrease of 0.48% from ¥4,543,352,930.71 at the end of the previous year[5] - The total current assets decreased slightly to CNY 2,616,014,317.82 from CNY 2,633,145,031.76, reflecting a decline of 0.65%[15] - The total liabilities decreased to CNY 845,385,207.46 from CNY 916,299,000.51, indicating a reduction of approximately 7.7%[17] - The equity attributable to shareholders of the parent company increased to CNY 3,037,602,730.81 from CNY 2,994,177,727.86, reflecting a growth of 1.4%[17] Research and Development - The company reported a 49.55% increase in R&D expenses, totaling ¥14,231,193.78 compared to ¥9,516,114.99 in the previous year[9] - The company's R&D expenses increased to CNY 14,231,193.78, up from CNY 9,516,114.99, marking a 49.5% rise year-over-year[18] - The company has plans for market expansion and new product development, as indicated by ongoing investments in research and development[14] - The company’s financial performance indicates a stable outlook with a focus on cost management and strategic investments in R&D[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,056, with the largest shareholder holding 44.60% of the shares[10] Other Significant Events - Government subsidies recognized in the current period amounted to ¥8,458,972.91, a 407.63% increase from ¥1,666,372.01 in the previous year[9] - The company is in the process of issuing A-shares to specific investors, which may involve related transactions[14] - The company has received compensation for part of the demolition from Zhejiang Tianfeng Pharmaceutical Factory, which may impact future cash flows[13] - The company is adjusting its management structure, including changes to the board secretary, which may influence operational efficiency[14] - The company did not conduct an audit for the Q1 2023 report[23]